A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This single-center, open-label, parallel group study will evaluate the effects of multiple doses of ketoconazole on the pharmacokinetics of single oral dose RO4602522 in healthy male volunteers. All subjects will receive a single oral dose of RO4602522 on Day 1. Subjects assigned to Group 2 will additionally receive ketoconazole (200 mg orally every 12 hours) from Day 1 to Day 17.
Effect of multiple doses of ketoconazole on RO4602522 single dose pharmacokinetics: Area under the concentration-time curve (AUC) [ Time Frame: Pre-dose and up to 10 hrs post-dose Day 1, and on Days 2-22 ]
Secondary Outcome Measures :
Safety: Incidence of adverse events [ Time Frame: approximately 3 months ]
RO4602522 metabolites: Plasma/urine concentrations [ Time Frame: Pre-dose and up to 10 hrs post-dose Day 1, and on Days 2-22 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy male subjects, 18 to 45 years of age, inclusive Healthy status is defined by absence of evidence of any active or chronic disease following detailed medical and surgical history and a complete physical examination
Body mass index (BMI) 18 to 30 kg/m2 inclusive
Male subjects and their partners of child-bearing potential must use two methods of contraception, one of which must be a barrier method, for the duration of the study and for 90 days after the last dose
Non-smoker (not having smoked since at least 3 months prior to screening)
History of alcohol abuse or drug addiction (including soft drugs like cannabis products)
Positive for hepatitis B, hepatitis C, or HIV infection
Participation in an investigational drug or device study within 90 days prior to screening
Concomitant disease or condition that could interfere with, or treatment of which might interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
History of any disease or condition that could alter the absorption, metabolism or elimination of drugs
Positive drug test and/or positive alcohol test
Positive cotinine test
Subject likely to need concomitant medication during the study period (including for dental conditions)
Any confirmed significant allergic reactions against any drug, or multiple allergies in the judgment of the investigator